Literature DB >> 20189749

Image quality in low-dose multidetector computed tomography: a pilot study to assess feasibility and dose optimization in whole-body bone imaging.

Tadhg G Gleeson1, Brenda Byrne, Pat Kenny, Jason Last, Patricia Fitzpatrick, Peter O'Gorman, Steven J Eustace.   

Abstract

OBJECTIVE: To study the impact of dose parameters on image quality at whole-body low-dose multidetector computed tomography (CT) in an attempt to derive parameters that allow diagnostic quality images of the skeletal system without incurring significant radiation dose in patients referred for investigation of plasma cell dyscrasias.
METHODS: By using a single cadaver, 14 different whole-body low-dose CT protocols were individually assessed by 2 radiologists, blinded to acquisition parameters (kVp and mAs, reconstruction algorithm, dose reduction software). Combinations of kVps that range from 80-140 kVp, and tube current time product from 14-125 mAs were individually scored by using a Likert scale from 1-5 in 4 separate anatomical areas (skull base, thoracic spine, pelvis, and distal femora). Correlation between readers scores and effective doses were obtained by using correlation coefficient statistical analysis, statistical significance was considered P < .01. Interobserver agreement was assessed by using a Bland and Altman plot. Interobserver agreement in each of the 4 anatomical areas was assessed by using kappa statistics. A single set of parameters was then selected for use in future clinical trials in a cohort of patients referred for investigation of monoclonal gammopathy, including multiple myeloma.
RESULTS: Several sets of exposure parameters allowed low-dose whole-body CT to be performed with effective doses similar to skeletal survey while preserving diagnostic image quality. Individual reader's and average combined scores showed a strong inverse correlation with effective dose (reader 1, r = -0.78, P = .0001; reader 2, r = -0.75, P = .0003); average combined scores r = -0.81, P < .0001). Bland and Altman plot of overall scores shows reasonable interobserver agreement, with a mean difference of 1.055.
CONCLUSION: Whole-body low-dose CT can be used to obtain adequate CT image quality to assess normal osseous detail while delivering effective doses similar to those associated with conventional radiographic skeletal survey.
Copyright © 2010 Canadian Association of Radiologists. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20189749     DOI: 10.1016/j.carj.2010.01.003

Source DB:  PubMed          Journal:  Can Assoc Radiol J        ISSN: 0846-5371            Impact factor:   2.248


  11 in total

1.  3D gastric computed tomography as a new imaging in patients with failure or complication after bariatric surgery.

Authors:  Marie-Cécile Blanchet; Caroline Mesmann; Mazen Yanes; Sébastien Lepage; Denis Marion; Patrick Gelas; Christian Gouillat
Journal:  Obes Surg       Date:  2010-12       Impact factor: 4.129

2.  Systematic Radiation Dose Reduction in Cervical Spine CT of Human Cadaveric Specimens: How Low Can We Go?

Authors:  M Tozakidou; C Reisinger; D Harder; J Lieb; Z Szucs-Farkas; M Müller-Gerbl; U Studler; S Schindera; A Hirschmann
Journal:  AJNR Am J Neuroradiol       Date:  2017-12-21       Impact factor: 3.825

Review 3.  Progress of modern imaging modalities in multiple myeloma.

Authors:  Toshiki Terao; Kosei Matsue
Journal:  Int J Hematol       Date:  2022-05-09       Impact factor: 2.490

4.  Role of whole-body 64-slice multidetector computed tomography in treatment planning for multiple myeloma.

Authors:  Ahmed Abdel Khalek Abdel Razek; Amany Ezzat; Emad Azmy; Nehal Tharwat
Journal:  Radiol Med       Date:  2012-09-17       Impact factor: 3.469

5.  Organ dose and total effective dose of whole-body CT in multiple myeloma patients.

Authors:  Robert Hemke; Kai Yang; Jad Husseini; Miriam A Bredella; F Joseph Simeone
Journal:  Skeletal Radiol       Date:  2019-10-15       Impact factor: 2.199

6.  Highly reduced-dose CT of the lumbar spine in a human cadaver model.

Authors:  Malte Lennart Warncke; Nis Jesper Wiese; Enver Tahir; Susanne Sehner; Axel Heinemann; Marc Regier; Klaus Püschel; Gerhard Adam; Julius Matthias Weinrich; Azien Laqmani
Journal:  PLoS One       Date:  2020-10-08       Impact factor: 3.240

7.  Whole Body Low Dose Computed Tomography Using Third-Generation Dual-Source Multidetector With Spectral Shaping: Protocol Optimization and Literature Review.

Authors:  Dario Baldi; Liberatore Tramontano; Vincenzo Alfano; Bruna Punzo; Carlo Cavaliere; Marco Salvatore
Journal:  Dose Response       Date:  2020-12-29       Impact factor: 2.658

8.  Ultra-Low-Dose Whole-Body Computed Tomography Protocol Optimization for Patients With Plasma Cell Disorders: Diagnostic Accuracy and Effective Dose Analysis From a Reference Center.

Authors:  Davide Tore; Osvaldo Rampado; Carla Guarnaccia; Roberto Mina; Maria Oronzio; Ambra Santonocito; Alessandro Serafini; Giulio Antonino Strazzarino; Laura Gianusso; Sara Bringhen; Paolo Fonio; Alessandro Depaoli
Journal:  Front Oncol       Date:  2021-11-17       Impact factor: 6.244

9.  Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group.

Authors:  Lia A Moulopoulos; Vassilis Koutoulidis; Jens Hillengass; Elena Zamagni; Jesus D Aquerreta; Charles L Roche; Suzanne Lentzsch; Philippe Moreau; Michele Cavo; Jesus San Miguel; Meletios A Dimopoulos; S Vincent Rajkumar; Brian G M Durie; Evangelos Terpos; Stefan Delorme
Journal:  Blood Cancer J       Date:  2018-10-04       Impact factor: 11.037

Review 10.  Whole-Body Low-Dose Multidetector-Row CT in Multiple Myeloma: Guidance in Performing, Observing, and Interpreting the Imaging Findings.

Authors:  Antonio Pierro; Alessandro Posa; Costanzo Astore; Mariacarmela Sciandra; Alessandro Tanzilli; Antonella Petrosino; Maria Saveria Del Balso; Vincenzo Fraticelli; Savino Cilla; Roberto Iezzi
Journal:  Life (Basel)       Date:  2021-11-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.